UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stock Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 12.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 269,725 shares of the biotechnology company’s stock after selling 38,965 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.17% of Ironwood Pharmaceuticals worth $1,111,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of IRWD. Stonepine Capital Management LLC increased its holdings in shares of Ironwood Pharmaceuticals by 1,982.8% in the 3rd quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company’s stock valued at $4,120,000 after acquiring an additional 951,988 shares during the period. BNP Paribas Financial Markets boosted its position in Ironwood Pharmaceuticals by 89.0% during the third quarter. BNP Paribas Financial Markets now owns 154,660 shares of the biotechnology company’s stock valued at $637,000 after purchasing an additional 72,815 shares in the last quarter. FMR LLC grew its stake in Ironwood Pharmaceuticals by 25.1% in the third quarter. FMR LLC now owns 169,681 shares of the biotechnology company’s stock valued at $699,000 after purchasing an additional 34,089 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in Ironwood Pharmaceuticals by 21.2% in the third quarter. Daiwa Securities Group Inc. now owns 67,570 shares of the biotechnology company’s stock worth $278,000 after purchasing an additional 11,800 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Ironwood Pharmaceuticals by 23.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock valued at $7,846,000 after buying an additional 364,841 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IRWD. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Finally, Leerink Partners began coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a “market perform” rating and a $5.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the sale, the chief financial officer now directly owns 309,572 shares in the company, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Stock Down 2.0 %

IRWD stock opened at $3.46 on Thursday. The stock has a market capitalization of $553.70 million, a PE ratio of -115.33 and a beta of 0.41. Ironwood Pharmaceuticals, Inc. has a 52 week low of $3.06 and a 52 week high of $15.70. The firm has a 50 day moving average of $3.98 and a 200 day moving average of $4.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. During the same quarter in the previous year, the firm posted $0.12 earnings per share. The company’s quarterly revenue was down 19.4% on a year-over-year basis. On average, equities research analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.08 earnings per share for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.